GeNeuro announces successful €6.0 million private placement

by admin | Jul 13, 2021 | Uncategorized

Geneva, Switzerland, July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as...

GeNeuro presents data supporting pathogenic role of an endogenous retroviral protein (HERV-W ENV) in post-COVID neuropsychiatric syndrome

by Christophe Guichard | Jul 5, 2021 | Uncategorized

Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic options for patients▪ Data provides a biologic rationale to the long-term neuropsychiatric symptoms affecting an important subset of post-COVID-19...

Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity

by Christophe Guichard | Apr 15, 2021 | Uncategorized

Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease...

GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting

by Christophe Guichard | Mar 2, 2021 | Uncategorized

DSMB confirms higher doses of temelimab in ProTEct-MS Phase 2 study are well tolerated▪ Study conducted at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm▪ Phase 2 top-line results on track to be reported in Q1 2022Geneva,...

Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

by Eclosion Team | Nov 3, 2020 | Uncategorized

Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), a biopharmaceutical company and the leader in NOX therapies, announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”; Nasdaq OMX –CALTX; NASDAQ -CALT) of 62.7% of Genkyotex in...

Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

by Eclosion Team | Oct 20, 2020 | Uncategorized

Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), abiopharmaceutical company andleader inNOXtherapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA)for...